BCL2 and B-cell chronic lymphocytic leukemia: Second, overexpressing Bcl-2 in DLBCL cell lines or primary human CLL cells did not result in sensitization of the cells towards BDA-366, as one would expect if the drug functioned by converting Bcl-2 into a proapoptotic Bax-activating protein, but rather had a protective effect.